During the last session, Aligos Therapeutics Inc. (NASDAQ:ALGS)’s traded shares were 0.13 million. At the end of the trading day, the stock’s price was $1.50, reflecting an intraday gain of 7.91% or $0.11. The 52-week high for the ALGS share is $17.97, that puts it down -1098.0 from that peak though still a striking 31.33% gain since the share price plummeted to a 52-week low of $1.03. The company’s market capitalization is $66.66M, and the average intraday trading volume over the past 10 days was 83050.0 shares, and the average trade volume was 308.11K shares over the past three months.
Aligos Therapeutics Inc. (ALGS) received a consensus recommendation of a Hold from analysts. That translates to a mean rating of 2.80. ALGS has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 3 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 0 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.67.
Aligos Therapeutics Inc. (NASDAQ:ALGS) trade information
Aligos Therapeutics Inc. (ALGS) registered a 7.91% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 7.91% in intraday trading to $1.50 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 20.97%, and it has moved by 6.38% in 30 days. Based on these gigs, the overall price performance for the year is -90.76%. The short interest in Aligos Therapeutics Inc. (NASDAQ:ALGS) is 0.61 million shares and it means that shorts have 1.86 day(s) to cover.
The consensus price target of analysts on Wall Street is $3.33, which implies an increase of 54.95% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $5.00 respectively. As a result, ALGS is trading at a discount of -233.33% off the target high and -33.33% off the low.
Aligos Therapeutics Inc. (ALGS) estimates and forecasts
Statistics show that Aligos Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Aligos Therapeutics Inc. (ALGS) shares have gone down -48.98% during the last six months, with a year-to-date growth rate more than the industry average at 9.01% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 15.20% this quarter and then jump 14.10% in the quarter after that. In the rating firms’ projections, revenue will decrease -37.60% compared to the previous financial year.
While earnings are projected to return -8.60% in 2022.
Aligos Therapeutics Inc. is due to release its next quarterly earnings between March 21 and March 25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Aligos Therapeutics Inc. (NASDAQ:ALGS)’s Major holders
Aligos Therapeutics Inc. insiders own 16.59% of total outstanding shares while institutional holders control 81.77%, with the float percentage being 98.04%. EcoR1 Capital, LLC is the largest shareholder of the company, while 121 institutions own stock in it. As of Mar 30, 2022, the company held over 3.95 million shares (or 9.25% of all shares), a total value of $8.49 million in shares.
The next largest institutional holding, with 3.55 million shares, is of Vivo Capital, LLC’s that is approximately 8.31% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $7.63 million.
Also, the Mutual Funds coming in first place with the largest holdings of Aligos Therapeutics Inc. (ALGS) shares are Federated Hermes Kaufmann Small Cap Fund and Vanguard Total Stock Market Index Fund. Data provided on Apr 29, 2022 indicates that Federated Hermes Kaufmann Small Cap Fund owns about 1.08 million shares. This amounts to just over 2.52 percent of the company’s overall shares, with a $1.27 million market value. The same data shows that the other fund manager holds slightly less at 0.68 million, or about 1.60% of the stock, which is worth about $1.47 million.